Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors

被引：0
|
作者：
Oziel-Taieb, S. [1 ]
Ferrara, R. [1 ]
Charrier, N. [1 ]
Maniry, J. [1 ]
Reichert, T. [1 ]
Brenot-Rossi, I [1 ]
Niccoli, P. [1 ]
机构：
[1] IPC Net Ctr, ENETS Ctr Excellence, Paoli Calmettes Inst, Marseille, France
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2024年 / 36卷
关键词：
neuroendocrine tumor; prrt; ludotatate; thrombocytopenia; bone metastasis; spleen;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H16
引用
收藏
页码：213 / 213
页数：1
相关论文
共 50 条
  • [21] 177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors
    Jimenez-Fonseca, P.
    Pubul, V
    Bello, P.
    Riesco-Martinez, M. D. C.
    Aller, J.
    Alonso, Garcia P.
    Caballero, E.
    Custodio, A.
    Centeno, Garcia R.
    Teule, A.
    Casanovas, Mitjavila M.
    Carmona-Bayonas, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 147 - 147
  • [22] Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Gupta, Santosh K.
    Singla, Suhas
    Bal, Chandrasekhar
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 593 - 599
  • [23] Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE
    Roth, Daniel
    Gustafsson, Johan
    Warfvinge, Carl Fredrik
    Sundlov, Anna
    Akesson, Anna
    Tennvall, Jan
    Gleisner, Katarina Sjogreen
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (03) : 399 - 405
  • [24] Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study
    Mitjavila Casanovas, M.
    Pubul, V.
    Bello, P.
    Miguel, B.
    Cano, J.
    Balaguer, D.
    Garcia-Burillo, A.
    Marino Mendez, A.
    Rodeno, E.
    Custodio, A.
    Pineiro, A.
    Garcia-Canamaque, L.
    Castellon, M.
    Orduna, M.
    Carmona-Bayonas, A.
    Jimenez-Fonseca, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S103 - S104
  • [25] Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
    Zidan, Lamiaa
    Iravani, Amir
    Oleinikov, Kira
    Ben-Haim, Simona
    Gross, David J.
    Meirovitz, Amichay
    Maimon, Ophra
    Akhurst, Tim
    Michael, Michael
    Hicks, Rodney J.
    Grozinsky-Glasberg, Simona
    Kong, Grace
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (02) : 218 - 225
  • [26] Use of PERCIST and RECIST for response evaluation in patients with neuroendocrine tumors treated with 177Lu-DOTATATE
    Gupta, Santosh
    Singla, Suhas
    Chakroborty, Sudipta
    Banerjee, Sharmila
    Das, Tapas
    Venkatesh, Meera
    Damle, Nishikant
    Bal, Chandrasekhar
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [27] Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate
    Chen, Luohai
    Gnanasegaran, Gopinath
    Mandair, Dalvinder
    Toumpanakis, Christos
    Caplin, Martyn
    Navalkissoor, Shaunak
    ENDOCRINE-RELATED CANCER, 2022, 29 (02) : 111 - 120
  • [28] COST-EFFECTIVENESS ANALYSIS OF RE-TREATMENT WITH 177LU-DOTATATE VERSUS NO RE-TREATMENT WITH 177LU-DOTATATE IN PATIENTS WITH PROGRESSIVE MIDGUT NEUROENDOCRINE TUMORS
    Leeuwenkamp, O.
    Mahon, R.
    Singh, M. K.
    Khare, A.
    VALUE IN HEALTH, 2020, 23 : S446 - S446
  • [29] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    ATOM INDONESIA, 2019, 45 (03) : 147 - 152
  • [30] A multicenter phase 2 randomised controlled trial comparing 177Lu-Dotatate and capecitabine combination treatment with 177Lu-Dotatate in neuroendocrine tumor patients
    Becx, M.
    Hofland, J.
    Nonnekens, J.
    Krenning, E.
    Wyld, D.
    Verburg, F.
    Brabander, T.
    de Herder, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S122 - S123
12345